60561-17-3

60561-17-3 structure
60561-17-3 structure

Name 2-hydroxypropane-1,2,3-tricarboxylic acid,N-[4-(methoxymethyl)-1-(2-thiophen-2-ylethyl)piperidin-4-yl]-N-phenylpropanamide
Synonyms EINECS 262-295-4
N-[4-(methoxymethyl)-1-(2-thiophen-2-ylethyl)-4-piperidyl]-N-phenylpropanamide citrate
UNII-S9ZFX8403R
N-(4-(methoxymethyl)-1-(2-(thiophen-2-yl)ethyl)piperidin-4-yl)-N-phenylpropionamide citrate
Sufentanyl citrate
sufentanil citrate
Sufenta
N-{4-(methoxymethyl)-1-[2-(2-thienyl)ethyl]-4-piperidyl}-N-phenylpropionamide citrate
N-[4-(methoxymethy)-1-[2-(2-thienyl)ethyl]-4-piperidinyl]-N-phenylpropanamide 2-hydroxy-1,2,3-propanetricarboxylate
Fentatienil
sufentanil cytrate
Boiling Point 493.1ºC at 760 mmHg
Melting Point 96.6ºC
Molecular Formula C28H38N2O9S
Molecular Weight 578.67400
Flash Point 252ºC
Exact Mass 578.23000
PSA 193.15000
LogP 2.90420
Appearance white to beige
Storage condition -20°C Freezer
Water Solubility H2O: soluble1mg/mL, clear

CHEMICAL IDENTIFICATION

RTECS NUMBER :
UE5295000
CHEMICAL NAME :
Propionanilide, N-(4-(methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperid yl)-, citrate
CAS REGISTRY NUMBER :
60561-17-3
LAST UPDATED :
199009
DATA ITEMS CITED :
9
MOLECULAR FORMULA :
C22-H30-N2-O2-S.C6-H8-O7
MOLECULAR WEIGHT :
578.74
WISWESSER LINE NOTATION :
T6NTJ DNR&V2 D1O1 A2- BT5SJ &QV1U1VQ -T

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
1200 ng/kg
TOXIC EFFECTS :
Behavioral - convulsions or effect on seizure threshold
REFERENCE :
AACRAT Anesthesia and Analgesia (New York). (Elsevier Science Pub. Co., Inc., 52 Vanderbilt Ave., New York, NY 10017) V.36- 1957- Volume(issue)/page/year: 66,91,1987
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
606 ng/kg/5M-C
TOXIC EFFECTS :
Behavioral - convulsions or effect on seizure threshold
REFERENCE :
AACRAT Anesthesia and Analgesia (New York). (Elsevier Science Pub. Co., Inc., 52 Vanderbilt Ave., New York, NY 10017) V.36- 1957- Volume(issue)/page/year: 66,91,1987
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
23 ug/kg/10M-C
TOXIC EFFECTS :
Vascular - BP lowering not characterized in autonomic section
REFERENCE :
AACRAT Anesthesia and Analgesia (New York). (Elsevier Science Pub. Co., Inc., 52 Vanderbilt Ave., New York, NY 10017) V.36- 1957- Volume(issue)/page/year: 65,703,1986
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
2777 ng/kg/3M-C
TOXIC EFFECTS :
Vascular - BP lowering not characterized in autonomic section
REFERENCE :
AACRAT Anesthesia and Analgesia (New York). (Elsevier Science Pub. Co., Inc., 52 Vanderbilt Ave., New York, NY 10017) V.36- 1957- Volume(issue)/page/year: 65,703,1986
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraspinal
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
1 ug/kg/20H-I
TOXIC EFFECTS :
Lungs, Thorax, or Respiration - dyspnea
REFERENCE :
ANASAB Anaesthesia. (Academic Press Inc. Ltd., 24-28 Oval Rd., London NW1 7DX, UK) V.1- 1946- Volume(issue)/page/year: 42,665,1987
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
17900 ug/kg
TOXIC EFFECTS :
Behavioral - analgesia
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 26,1548,1976
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
18700 ug/kg
TOXIC EFFECTS :
Behavioral - convulsions or effect on seizure threshold
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 26,1551,1976
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
14100 ug/kg
TOXIC EFFECTS :
Peripheral Nerve and Sensation - flaccid paralysis without anesthesia (usually neuromuscular blockage) Behavioral - altered sleep time (including change in righting reflex) Behavioral - convulsions or effect on seizure threshold
REFERENCE :
ARZNAD Arzneimittel-Forschung. Drug Research. (Editio Cantor Verlag, Postfach 1255, W-7960 Aulendorf, Fed. Rep. Ger.) V.1- 1951- Volume(issue)/page/year: 26,1551,1976
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - guinea pig
DOSE/DURATION :
11800 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
MDACAP Medicamentos de Actualidad. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1965- Volume(issue)/page/year: 21,210,1985
Symbol GHS02 GHS06 GHS08
GHS02, GHS06, GHS08
Signal Word Danger
Hazard Statements H225-H301 + H311 + H331-H370
Precautionary Statements P210-P260-P280-P301 + P310-P311
Hazard Codes T+,T,F
Risk Phrases 26/27/28-39/23/24/25-23/24/25-11
Safety Phrases 26-27-28-36/37/39-45-36/37-16-7
RIDADR UN 3249
Packaging Group III
Hazard Class 6.1(b)

~55%

60561-17-3 structure

60561-17-3

Literature: AUSPEX PHARMACEUTICALS, INC. Patent: US2010/16365 A1, 2010 ; Location in patent: Page/Page column 27 ; US 20100016365 A1
Precursor  2

DownStream  0